期刊文献+

沙利度胺治疗系统性红斑狼疮皮肤黏膜损害疗效观察 被引量:3

下载PDF
导出
摘要 系统性红斑狼疮(systemic lupus erythematosus,SLE)属自身免疫性疾病,皮肤黏膜损害是SLE最常见的临床表现之一,也是SLE诊断依据之一。迄今为止,糖皮质激素和细胞毒药物仍是治疗红斑狼疮最有效的方法,但仍有20%~30%患者无效。笔者应用小剂量沙利度胺治疗SLE皮肤黏膜损害39例,疗效满意,报道如下。
作者 王文琴
出处 《浙江中西医结合杂志》 2010年第12期748-750,共3页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献6

二级参考文献58

  • 1Morel L. Genetics of human lupus nephritis. Semin Nephrol, 2007, 27: 2-11.
  • 2Yasui K, Kobayashi N, Yamazaki T, et al. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation.Curt Pharm Des. 2005, 11: 395-401.
  • 3Hirashima M, Fukazawa T, Abe K, et al. Expression and activity analyses of CTLA4 in peripheral blood lymphoeytes in systemic lupus erythematosus patients. Lupus, 2004, 13:24-31.
  • 4Bmnner-Weinzierl MC, Hoff H, Burmester GR. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases. Arthritis Res Ther, 2004, 6: 45-54.
  • 5Lopez P, Gomez J, Mozo L, et al. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthritis Res Ther, 2006, 8: R42.
  • 6Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus:a rationale for therapeutic intervention. Lupus, 2004, 13: 344-347.
  • 7Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis
  • 8Coleman M, Leonard JP, Nahum K,et al. Non-myelosuppressive therapy with blt-d [Bianxin(r), low dose thalidomide and dexamethasone] is highly active in Waldenstrom's macroglobulinemia and myeloma. Blood, 2000, 96: 167.
  • 9Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis, 2000, 59:428-433.
  • 10Hashimoto Y. Novel biological response modifiers derived from thalidomide. Curr Med Chem, 1998, 5: 163-178.

共引文献38

同被引文献57

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部